Goldman Sachs’s Immune Design Corp. IMDZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q2 | – | Sell |
-35,567
| Closed | -$208K | – | 5549 |
|
|
2019
Q1 | $208K | Sell |
35,567
-37,342
| -51% | -$127K | ﹤0.01% | 4780 |
|
|
2018
Q4 | $95K | Buy |
72,909
+8,765
| +14% | +$15.2K | ﹤0.01% | 5005 |
|
|
2018
Q3 | $221K | Buy |
64,144
+11,368
| +22% | +$42.7K | ﹤0.01% | 4874 |
|
|
2018
Q2 | $240K | Buy |
52,776
+34,054
| +182% | +$136K | ﹤0.01% | 4907 |
|
|
2018
Q1 | $62K | Buy |
18,722
+840
| +5% | +$2.97K | ﹤0.01% | 5416 |
|
|
2017
Q4 | $70K | Buy |
+17,882
| New | +$97.4K | ﹤0.01% | 5850 |
|
|
2017
Q3 | – | Sell |
-29,878
| Closed | -$291K | – | 7145 |
|
|
2017
Q2 | $291K | Buy |
+29,878
| New | +$210K | ﹤0.01% | 5534 |
|
|
2016
Q4 | – | Sell |
-15,378
| Closed | -$117K | – | 7337 |
|
|
2016
Q3 | $117K | Buy |
+15,378
| New | +$112K | ﹤0.01% | 6152 |
|
|
2015
Q4 | – | Sell |
-31,027
| Closed | -$379K | – | 7691 |
|
|
2015
Q3 | $379K | Sell |
31,027
-21,843
| -41% | -$409K | ﹤0.01% | 5412 |
|
|
2015
Q2 | $1.09M | Buy |
52,870
+39,626
| +299% | +$936K | ﹤0.01% | 4463 |
|
|
2015
Q1 | $280K | Sell |
13,244
-23,408
| -64% | -$611K | ﹤0.01% | 5714 |
|
|
2014
Q4 | $1.13M | Buy |
36,652
+7,954
| +28% | +$221K | ﹤0.01% | 4429 |
|
|
2014
Q3 | $507K | Buy |
+28,698
| New | +$363K | ﹤0.01% | 5254 |
|
Goldman Sachs's IMDZ Position: Q2 2019 in Review
Goldman Sachs sold out of Immune Design Corp. (IMDZ) in Q2 2019, closing a stake of 35,567 shares — an estimated $208K sold.
Goldman Sachs first reported a position in IMDZ in Q3 2014 and held it in 13 quarters. The position peaked at $1.13M in Q4 2014. 0 funds tracked by Wall St. Rank hold IMDZ as of Q2 2019.
- Goldman Sachs reported no remaining Immune Design Corp. position as of Q2 2019 after selling out during the quarter.
- Goldman Sachs sold 35,567 Immune Design Corp. shares in Q2 2019, an estimated $208K.
- Goldman Sachs first reported a position in Immune Design Corp. in Q3 2014 and held it in 13 quarters.
- Goldman Sachs's Immune Design Corp. position peaked at $1.13M in Q4 2014.
- 0 funds tracked by Wall St. Rank held Immune Design Corp. as of Q2 2019.
Based on Goldman Sachs's 13F filing for Q2 2019, filed 14 Aug 2019.